JENNIFER STODDARD: Open Payments
NPI 1588175772 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$727 in 21 payments from 9 companies in 2025. Trend: 2023 $919 · 2024 $997 · 2025 $727
Food & beverage: $727
| Company | Payments | Amount |
|---|---|---|
| AKEBIA THERAPEUTICS INC | 4 | $171 |
| Novartis Pharmaceuticals Corporation | 6 | $147 |
| AstraZeneca Pharmaceuticals LP | 1 | $120 |
| Bard Peripheral Vascular, Inc. | 1 | $77 |
| Ardelyx, Inc. | 3 | $72 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Aurinia Pharma U.S., Inc. | 2 | $43 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| Amgen Inc. | 1 | $20 |
Products named: Vafseo, LOKELMA, Pristine, IBSRELA, JYNARQUE, LUPKYNIS, Auryxia, RAYALDEE.
Industry payments across CA — which companies pay providers there.
